Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics.Royalty Pharma plc (Nasdaq: RPRX)…
Royalty Pharma’s $1.5 Billion Acquisition of PTC Therapeutics’ Royalties
